GSK’s COPD Drug Gets A New Name (Breo) But May Face Familiar Challenges At FDA Panel
This article was originally published in The Pink Sheet Daily
Executive Summary
The respiratory drug’s fate is uncertain given its mixed Phase III trial results; in two pivotal studies Breo, formerly Relovair, failed to demonstrate superiority to GSK’s Advair.
You may also be interested in...
Further Mixed Results For GSK/Theravance’s Relovair Have Investors Holding Breath
GSK and Theravance released preliminary results of two Phase III studies for their COPD drug Relovair that could serve to help differentiate the drug from Advair.
Relovair Data Raises Respiratory Stakes For GSK And Theravance
Mixed Phase III data results on GSK/Theravance’s once-daily follow-up to Advair raises the regulatory and commercial stakes for the drug, a crucial pipeline product for both companies
Rejecting PhRMA's Request, US FDA Sticks With Size Over Function In Defining Biologic
Agency's final rule defines protein based on size of amino acid sequence, irrespective of method of manufacture, saying this 'bright-line rule' provides regulatory certainty.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: